The bill proposes significant changes to the Uniform Controlled Substances Act by revising Section 21-28-1.02, which defines various terms related to controlled substances, and replacing it with a new version that will take effect on January 1, 2023. This new section aims to modernize the language surrounding controlled substances and introduces updated definitions, including "acute pain," "chronic intractable pain," and "opioid therapy."

The bill clarifies the authority of practitioners in prescribing and administering controlled substances, establishing that initial prescriptions for opioids for acute pain must not exceed a seven-day supply. It emphasizes the need for comprehensive pain assessments before initiating opioid therapy. Additionally, the bill introduces specific regulations for practitioners prescribing opioids to minors, including limits on dosage and requirements for discussing risks and alternatives with patients or guardians.

It mandates thorough record-keeping and a review of the prescription drug monitoring program prior to initiating opioid therapy. The bill also repeals the existing Intractable Pain Treatment Act, replacing it with updated guidelines for prescribing controlled substances for chronic pain. Importantly, it clarifies that practitioners will not face disciplinary action for prescribing controlled substances for therapeutic purposes to patients with intractable pain, provided that such treatments are properly documented. Overall, the bill aims to enhance the regulation of controlled substances while ensuring responsible prescribing practices.

Statutes affected:
7923: 21-28-1.02
7923  SUB A: 21-28-1.02